A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.

被引：9
|
作者：
LoRusso, Patricia
Gounder, Mrinal M.
Patel, Manish R.
Yamamoto, Noboru
Bauer, Todd Michael
Laurie, Scott
Grempler, Rolf
Davenport, Teffany
Geng, Junxian
Rohrbacher, Maren
Lahmar, Mehdi
机构：
[1] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Florida Canc Specialists & Res Inst, Sarah Cannon Res Inst, Sarasota, FL USA
[4] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[5] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[6] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[8] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[9] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3016
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase I/Ib dose-escalation study of aveluma in Chinese patients with advanced solid tumors
    Wu, Yi-Long
    Cheng, Ying
    Chen, Huajun
    Tu, Haiyan
    Xu, Chongrui
    Wang, Zhen
    Liu, Ying
    Xin, Ying
    Lou, Haizhou
    Wang, Wei
    Chin, Kevin
    Li, Dandan
    Zhao, Di
    Gao, Yanfei
    Xu, Wenping
    Pan, Hongming
    FUTURE ONCOLOGY, 2022,
  • [32] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Padda, Sukhmani K.
    Krupitskaya, Yelena
    Chhatwani, Laveena
    Fisher, George A.
    Colevas, Alexander D.
    Pedro-Salcedo, Melanie San
    Decker, Rodney
    Latz, Jane E.
    Wakelee, Heather A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1013 - 1020
  • [33] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
    Robert, Francisco
    Sandler, Alan
    Schiller, Joan H.
    Liu, Glenn
    Harper, Karen
    Verkh, Lev
    Huang, Xin
    Ilagan, Jennifer
    Tye, Lesley
    Chao, Richard
    Traynor, Anne M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (04) : 669 - 680
  • [34] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
    Francisco Robert
    Alan Sandler
    Joan H. Schiller
    Glenn Liu
    Karen Harper
    Lev Verkh
    Xin Huang
    Jennifer Ilagan
    Lesley Tye
    Richard Chao
    Anne M. Traynor
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 669 - 680
  • [35] PHASE IB DOSE-ESCALATION STUDY OF THE AKT INHIBITOR IPATASERTIB (IPAT) WITH PACLITAXEL (P) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS
    Isakoff, S. J.
    Infante, J. R.
    Juric, D.
    Chan, W. Y.
    Jia, S.
    Musib, L.
    Zhu, J.
    Meng, R.
    Patel, P. H.
    Bendell, J. C.
    ANNALS OF ONCOLOGY, 2014, 25
  • [36] A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors
    Gordon, Michael S.
    Springett, Gregory M.
    Su, Yungpo Bernard
    Ould-Kaci, Mahmoud
    Wind, Sven
    Zhao, Yihua
    LoRusso, Patricia M.
    FUTURE ONCOLOGY, 2015, 11 (10) : 1479 - 1491
  • [37] A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
    Harding, James J.
    Telli, Melinda
    Munster, Pamela
    Voss, Martin H.
    Infante, Jeffrey R.
    DeMichele, Angela
    Dunphy, Mark
    Le, Mai H.
    Molineaux, Chris
    Orford, Keith
    Parlati, Frank
    Whiting, Sam H.
    Bennett, Mark K.
    Tannir, Nizar M.
    Meric-Bernstam, Funda
    CLINICAL CANCER RESEARCH, 2021, 27 (18) : 4994 - 5003
  • [38] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Sukhmani K. Padda
    Yelena Krupitskaya
    Laveena Chhatwani
    George A. Fisher
    Alexander D. Colevas
    Melanie San Pedro-Salcedo
    Rodney Decker
    Jane E. Latz
    Heather A. Wakelee
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1013 - 1020
  • [39] Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors
    Wu, Yi-Long
    Cheng, Ying
    Chen, Huajun
    Tu, Haiyan
    Xu, Chongrui
    Wang, Zhen
    Liu, Ying
    Xin, Ying
    Lou, Haizhou
    Wang, Wei
    Chin, Kevin
    Li, Dandan
    Zhao, Di
    Gao, Yanfei
    Xu, Wenping
    Pan, Hongming
    FUTURE ONCOLOGY, 2022, 18 (17) : 2053 - 2062
  • [40] A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
    Shapiro, Geoffrey
    Mier, James Walter
    Hilton, John Frederick
    Gandhi, Leena
    Chau, Nicole G.
    Bullock, Andrea J.
    Supko, Jeffrey G.
    Verselis, Sigitas Jonas
    Murgo, Kayla
    Sze, Cameron
    Gotthardt, Susan
    Wolanski, Andrew
    Alexander, W. James
    Kumar, Ashok
    Holden, Sylvia Adell
    Chafai-Fadela, Karima
    Ram, Siya
    Menon, Krishna E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345